bg-img9.jpg
8.jpg
World Stem Cells & Regenerative Medicine Congress


We are pleased to announce our participation at the 11th Annual World Stem Cells & Regenerative Medicine Congress on May 18-20 in London, England. In the past, this event focused on developments in stem cell therapies and innovations within regenerative medicine. As the industry progresses, this year's conference will focus on the cell therapies that have made it to market, the innovations of academia and universities, and the use of stem cells for drug discovery. Additionally, this year's event will be co-located with World Precision Medicine Congress and the Cord Blood World Europe.

Topic: Biobanking and Biorepository, Topic: Cell T..........

InsideAccess: Maintaining Inventory Accuracy

In an age of electronic databases and barcode scanning, maintaining inventory accuracy should be simple. Vials are put in a freezer and the location is recorded in a database. How could sample storage be complicated?

It’s true that technology has improved efficiency and accuracy in the management of all types of inventory. However, whether the inventory in question is lego blocks or vials of blood, inventory management is more complicated than it seems. Even with the most sophisticated electronic tools, multiple challenges remain.

Last August we introduced a new content series called InsideAccess to give you inside look into our operations and processes. In this edition of InsideAccess we'll take a look at the challenges involved in maintaining inventory accuracy and some of the tools we use in working toward our goal of absolute, 100%, accuracy in our operations.

Topic: Biobanking and Biorepository, Content: Insi..........

Pooling Biospecimen Collections into “Synthetic” Cohorts to Promote Personalized Medicine

Large longitudinal studies have become impractical on many levels. At well over $100 per patient enrolled, the traditional large cohort study has become cost-prohibitive. Nor is cost the only factor: another is time. By their very nature, cohort studies can take decades to yield benefits, both at the individual as well as the population level.1 However, these studies are still needed both for public health research and to support the implementation of personalized medicine.

Topic: Biobanking and Biorepository, Topic: Public..........

The Evolution of Public Health Research: Sir Austin Bradford Hill and the Cigarette-Rolling Machine

In 1923, a general practitioner in rural Virginia received a phone call from a friend, a surgeon at a hospital in Richmond. A middle-aged man with an uncommon form of cancer had been admitted to the hospital - would he like to come and see the patient, the friend asked. It was a rare opportunity to examine and diagnose an unusual illness first-hand. The country doctor was happy to visit the hospital and further his education, especially since he'd doubted seeing more than one or two similar patients over the rest of his career.

Topic: Biobanking and Biorepository, Topic: Labora..........

ISBER 2016 Annual Meeting: Sample Integrity You Can Bank On

We are pleased to announce our participation at the International Society for Biological and Environmental Repositories (ISBER) 2016 Annual Meeting in Berlin, Germany. This year's theme, Breaking Down Walls: Unifying Biobanking Communities to Secure our Sustainability, will focus on different fields of biobanking and how biobanking communities can act in concert to increase sustainability and to secure the future of biobanking. ISBER 2016 is the premier global event in the field of repository and specimen management and we are honored to showcase our services and products in conjunction with our parent company, Thermo Fisher Scientific at Booth #63.

Topic: Biobanking and Biorepository, Content: Blog

Managing the Cold Chain to Minimize Pre-Analytical Variability: ISBER 2015 Flashback

The value of your work lies in the integrity of your specimens. Ensuring samples are maintained at the proper temperature throughout all processes is imperative to maximal long term viability and usability. This means not only during the processing and preparation of samples for analysis or storage—it also means during the transportation process. Moving samples between physical locations is a necessary part of biobanking, whether the locations are separated by a lab, a building or even a continent.

With ISBER 2016 right around the corner, let's take a trip down memory lane and review last year's workshop, presented by Alex Esmon PhD, global cold storage product manager at Thermo Fisher Scientific, on the importance of maintaining the cold chain during sample transport.

Topic: Biobanking and Biorepository, Content: Blog

Large-Scale Freezing of Biologics: Advantages and Challenges

Biopharmaceutical companies often produce millions of units of bulk biological materials that are then distributed for clinical use. This represents a significant supply chain challenge, as these materials need to be maintained within very specific environmental parameters. Temperature, humidity, and stress during material handling must be tightly controlled to prevent degradation of quality. Large-scale freezing of biologics provides a safe and effective method of storing biological materials, but this approach comes with unique challenges.

Topic: Biobanking and Biorepository, Topic: Cold-C..........

The Growing Public Health Concern Surrounding Zika

Over the past several weeks, the Zika virus has morphed from an obscure disease into an international public health emergency, gaining global attention. This has left the public health research community with many questions; Where did the disease originate? How is it transmitted? How do we work together to develop and distribute a vaccine?

In this blog we'll explore the existing information surrounding the Zika virus and some of the challenges associated with vaccine development.

Topic: Biobanking and Biorepository, Topic: Cold-C..........

The Shift to Immunosurveillance in Breast Cancer Treatment

As we've discussed previously on the blog, bio-pharmaceutical entities are scrambling to bring new immunotherapies to the clinic, particularly in the treatment of cancers. The US Food and Drug Administration (FDA) and other regulatory agencies worldwide have already approved several immunotherapies for the treatment of various tumors, including melanoma and non-small cell lung carcinoma (NSCLC). However, pre-clinical and clinical trials to assess the safety and efficacy of investigational immunotherapies for breast cancer have only recently begun.

Topic: Biobanking and Biorepository, Topic: Cell T..........

A Paradigm Shift in Biobanking: The Future of Cell Preservation Strategies

Once considered “old school,” cryopreservation is going through another scientific and technological development growth phase. Today’s new cryopreservation processes and products promise to deliver disruptive technologies to discovery science, stem cell research, diagnostics and personalized medicine; forever changing the future of cell preservation strategies.

Cell preservation has evolved from simple, often poorly annotated private collections of clinical specimens to highly organized and well-annotated collections maintained by commercial and not-for-profit organizations. Currently, the focus of cell preservation strategies is from government and international agencies on the activities of biobanks, specifically on the need to adopt best practices and to provide scientific, legal and ethical guidelines for the biopreservation industry. Cell preservationists still focus on fulfilling the immediate post-thaw viability needs of today’s researchers.

Topic: Biobanking and Biorepository, Topic: Cell T..........

The Evolution of Public Health Research: Snow’s Dilemma

Since the dawn of humanity, we have observed nature and hypothesized reasons behind how and why things happen. With the development of civilization, we standardized the methods with which we test, observe, and analyze nature, and this gave birth to the field of science. As far as the defined field of study now known as Epidemiology and Public Health, it can be argued that it began in 1854, with a cholera outbreak in the Soho district of London and a physician named John Snow (who knew more than nothing).

Topic: Biobanking and Biorepository, Topic: Public..........

What You Need to Know About The Biomarkers Consortium

Established in 2006, The Biomarkers Consortium (BC) is a public-private partnership whose mission is to identify, develop and seek regulatory approval for new biological markers (biomarkers) to accelerate the detection, diagnosis and treatment of many diseases. These biomarkers support the development of new preventative medical measures, medical diagnostics and drug development.

Topic: Biobanking and Biorepository, Topic: Clinic..........